Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Breaks Below Two Hundred Day Moving Average – Should You Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s share price passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $32.50 and traded as low as $31.65. Agios Pharmaceuticals shares last traded at $31.80, with a volume of 569,934 shares changing hands.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on AGIO shares. JPMorgan Chase & Co. upped their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Truist Financial reduced their price objective on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Royal Bank Of Canada boosted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, September 21st. Finally, Bank of America raised their price target on Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $41.75.

Agios Pharmaceuticals Stock Down 2.1%

The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -4.54 and a beta of 0.63. The company’s 50-day simple moving average is $33.37 and its 200 day simple moving average is $32.50.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The company had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. On average, equities analysts expect that Agios Pharmaceuticals, Inc. will post -5.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the completion of the sale, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGIO. Sei Investments Co. grew its stake in Agios Pharmaceuticals by 342.8% in the 1st quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $2,150,000 after buying an additional 49,198 shares during the last quarter. SCS Capital Management LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth $22,743,000. Seven Fleet Capital Management LP acquired a new position in Agios Pharmaceuticals during the 4th quarter worth $864,000. GW&K Investment Management LLC boosted its holdings in Agios Pharmaceuticals by 41.5% during the fourth quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock valued at $32,863,000 after acquiring an additional 354,359 shares during the period. Finally, Parkman Healthcare Partners LLC bought a new stake in Agios Pharmaceuticals during the second quarter valued at about $24,828,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases. Based in Cambridge, Massachusetts, the company specializes in cellular metabolism and the development of therapies designed to address underlying disease biology rather than only treating symptoms.

Agios’ lead commercial product is Pyrukynd (mitapivat), an oral pyruvate kinase activator approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.